Our team is interested in translational research in sickle cell disease, with the goal of helping to develop new therapies for sickle cell disease. We initiated and completed a phase I trial of intravenous gammaglobulin for pain crisis, and we are currently studying the utility of haptoglobin and/or hemopexin replacement therapy. We are also interested in studying cellular therapy aspects of sickle cell disease, such as plerixafor mobilization of hematopoietic stem cells for gene therapy and autologous cord blood characteristics.

Hematology